HEDIS[®] Tips: Follow-Up After Emergency Department Visit for Substance Use (FUA)

MEASURE DESCRIPTION

The percentage of emergency department (ED) visits for patients 13 years of age and older with a principal diagnosis of substance use disorder (SUD), or any diagnosis of drug overdose, for which there was follow-up. Two rates are reported:

- 1. The percentage of ED visits for which the patient received follow-up within 30 days of the ED visit (31 total days).
- 2. The percentage of ED visits for which the patient received follow-up within 7 days of the ED visit (8 total days).

CODES INCLUDED IN THE CURRENT HEDIS® MEASURE

Description	Code
Codes to Identify AOD Abuse and Dependence	ICD-10CM: F10.10, F10.120, F10.121, F10.129-F10.132, F10.139, F10.14, F10.150, F10.151, F10.159, F10.180-F10.182, F10.188, F10.19, F10.20, F10.220, F10.221, F10.229-F10.232, F10.239, F10.24, F10.250, F10.251, F10.259, F10.26, F10.27, F10.280-F10.282, F10.288, F10.29, F11.10, F11.120-F11.122, F11.129, F11.13, F11.14, F11.150, F11.151, F11.159, F11.181, F11.182, F11.188, F11.19, F11.20, F11-220-F11.222, F11.229, F11.23, F11.24, F11.250, F11.251, F11.259, F11.281, F11.282, F11.288, F12.19, F12.20, F12.20-F12.222, F12.229, F12.23, F12.250, F12.251, F12.259, F12.280, F12.288, F12.29, F13.10, F13.120, F13.121, F13.129-F13.132, F13.139, F13.14, F13.150, F13.151, F13.159, F13.180-F13.182, F13.188, F13.19, F13.20, F13.220, F13.221, F13.229-F13.232, F13.239, F13.24, F13.250, F13.251, F13.259, F13.26, F13.27, F13.280-F13.282, F13.288, F13.29, F14.10, F14.120-F14.122, F14.129, F14.13, F14.14, F14.150, F14.151, F14.159, F14.180-F14.182, F14.188, F14.19, F14.20, F14.220-F14.222, F14.229, F14.23, F14.24, F14.250, F14.251, F14.259, F14.280-F14.282, F14.288, F14.29, F15.10, F15.120-F15.122, F15.129, F15.13, F15.14, F15.150, F15.151, F15.159, F15.180-F15.182, F15.188, F15.19, F15.20, F15.220-F15.222, F15.229, F15.23, F14.280-F14.282, F14.288, F14.29, F15.180, F15.182, F15.188, F15.19, F15.20, F15.220, F15.220, F15.220, F15.220, F15.221, F16.220, F16.221, F16.122, F16.124, F16.50, F16.51, F16.259, F16.288, F15.29, F16.10, F16.120-F16.122, F16.129, F16.14, F16.150, F16.151, F16.159, F16.180, F16.183, F16.188, F16.19, F16.20, F16.220, F16.221, F16.229, F16.24, F16.250, F16.251, F18.250, F18.251, F18.259, F18.260, F18.288, F16.29, F18.10, F18.120, F18.220, F18.221, F18.229, F18.24, F18.250, F18.251, F18.259, F18.27, F18.280, F18.280, F18.20, F18.220, F18.221, F18.229, F18.24, F18.250, F18.251, F18.259, F18.27, F18.280, F18.288, F18.20, F18.121, F18.229, F18.24, F18.250, F18.251, F18.259, F18.27, F19.280, F18.288, F18.29, F19.10, F19.120-F19.122, F19.129-F10.132, F19.139, F19.14, F19.150, F19.151, F19.159, F19.16, F19.17, F19.180-F19
Codes to Induce Disorders	ICD-10CM: F10.920, F10.921, F10.929-F10.932, F10.939, F10.94, F10.950, F10.951, F10.959, F10.96, F10.97, F10.980-F10.982, F10.988, F10.99, F11.90, F11.920-F11.922, F11.929, F11.93, F11.94, F11.950, F11.951, F11.959, F11.981, F11.982, F11.988, F11.99, F12.90, F12.920-F12.922, F12.929, F12.93, F12.950, F12.951, F12.959, F12.980, F12.988, F12.99, F13.90, F13.920, F13.921, F13.929-F13.932, F13.939, F13.94, F13.950, F13.951, F13.959, F13.96, F13.97, F13.980-F13.982, F13.988, F13.99, F14.90, F14.920-F14.922, F14.929, F14.93, F14.94, F14.950, F14.951, F14.959, F14.980-F14.982, F14.988, F14.99, F15.90, F15.920-F15.922, F15.929, F15.93, F15.94, F15.950, F15.951, F15.951, F15.959, F15.980-F15.982, F15.988, F15.99, F16.90, F16.920, F16.921, F16.929, F16.94, F16.950, F16.951, F16.959, F16.980, F16.983, F16.988, F16.99, F18.90, F18.920, F18.921, F18.929, F18.94, F18.950, F18.951, F18.950, F18.97, F18.980, F18.988, F18.99, F19.90, F19.920-F19.922, F19.929-F19.932, F19.939, F19.94, F19.950, F19.951, F19.959, F19.96, F19.97, F19.980-19.982, F19.988, F19.99

The Healthcare Effectiveness Data and Information Set (HEDIS®) is a registered trademark of NCQA. The NCQA HEDIS measure specification has been adjusted pursuant to NCQA's *Rules for Allowable Adjustments of HEDIS*. The adjusted measure specification may be used only for internal quality improvement purposes. Updated 2/1/2022



	1
Unintentional Drug Overdose	ICD-10CM : T40.0X1A, T40.0X1D, T40.0X1S, T40.0X4A, T40.0X4D, T40.0X4S, T40.1X1A, T40.1X1D, T40.1X1S, T40.1X4A, T40.1X4D, T40.1X4S, T40.2X1A, T40.2X1D, T40.2X1S, T40.2X4A, T40.2X4D, T40.2X4S, T40.3X1A, T40.3X1D, T40.3X1S, T40.3X4A, T40.3X4D, T40.3X4S, T40.411A, T40.411D, T40.411S, T40.414A, T40.414D, T40.414S, T40.421A, T40.421D, T40.421S, T40.424A, T40.424D, T40.424S, T40.491D, T40.491D, T40.491S, T40.494A, T40.494D, T40.494S, T40.5X1A, T40.5X1D, T40.5X1S, T40.5X4A, T40.5X4D, T40.5X4S, T40.601A, T40.601D, T40.601S, T40.604A, T40.604D, T40.604S, T40.691A, T40.691D, T40.691S, T40.604A, T40.694D, T40.694S, T40.7X1A, T40.7X1D, T40.7X1S, T40.7X4A, T40.7X4D, T40.7X4S, T40.8X1A, T40.8X1D, T40.8X1S, T40.991A, T40.991D, T40.991S, T40.901D, T40.901S, T40.904A, T40.904D, T40.904S, T40.991A, T40.991D, T40.991S, T41.091D, T41.0X1S, T41.0X1S, T41.0X4A, T41.0X4D, T41.0X4S, T41.1X1A, T41.1X1D, T41.1X1S, T41.1X4A, T41.1X4D, T41.1X4S, T41.201A, T41.201D, T41.201S, T41.204A, T41.204D, T41.204S, T41.291A, T41.291D, T41.3X4S, T41.3X4S, T41.41XA, T41.41XD, T41.41XS, T41.41XA, T41.41XD, T41.41XS, T42.3X1A, T42.3X1D, T42.3X1S, T42.3X4A, T42.3X4D, T42.3X4S, T42.4X1A, T42.4X1D, T42.3X1B, T42.3X1D, T42.3X1S, T43.601A, T43.601D, T43.601S, T43.604A, T43.604D, T43.604S, T43.621A, T43.621D, T43.621S, T43.624A, T43.624D, T43.624D, T43.624S, T43.604A, T43.631D, T43.631S, T43.634A, T43.634D, T43.694A, T43.694D, T43.694D, T43.694S, T51.0X1A, T51.0X1D, T43.604S, T51.0X4A, T51.0X4D, T43.604S, T43.694A, T43.694D, T43.694D, T43.694S, T51.0X1A, T51.0X1D, T51.0X4B, T51.0X4A, T51.0X4B, T51.
Follow-up visits	CPT®: 98960-98962, 98966-98972, 99078, 99201-99205, 99211-99215,99217-99220, 99241- 99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99421-99423, 99441-99444, 99457, 99483, 99492-99494, 99510 HCPCS: G0071, G0155, G0176, G0177, G0396, G0397, G0409-G0411, G0443, G0463, G0512, G2010, G2012, G2061-G2063, H0001, H0002, H0004, H0005, H0007, H0015, H0016, H0022, H0031, H0036, H0037, H0039, H0040, H0047, H2000, H2001, H2010, H2011, H2013- H2020, H2035, H2036, S0201, S9480, S9484, S9485, T1006, T1012, T1015 UBREV: 0510, 0513, 0515, 0516, 0517, 0519-0523, 0526-0529, 0900, 0902-0904, 0911, 0914-0917, 0919, 0944, 0945, 0982, 0983 Telephone Visits - CPT®: 98966-98968, 99441-99443 Online Assessments - CPT®: 98969-98972, 99421-99423, 99444, 99457
Telehealth Modifier	95, GT with POS: 02

HOW TO IMPROVE HEDIS® SCORES

- Schedule a follow-up visit within 7 days and at least two additional visits within 30 days or refer immediately to a PCP or behavioral health provider when giving a diagnosis of alcohol or other drug dependence. Telephone and/or telehealth appointments within the required timeframe meets compliance.
- Refer the member to a Molina Care Manager or work collaboratively with the Molina Care Manager if one is already assigned to help increase member's access and motivation for treatment.
- Follow-up visits must be supported by a claim, encounter or note from the mental health practitioner's medical chart in order to count toward the measure.
- Document identified substance abuse in the patient chart and submit a claim with the correct billing codes.
- Review situations where there are comorbid medical conditions. Be sure to include all diagnoses and use substance use related codes (ex. Cellulitis- L03.90 related to Intravenous Drug use F11.20) as these also qualify patients for the measures.
- Provide patient educational materials and resources that include information on the treatment processes and options, including mutual support groups and other community-based programs.

"The USPSTF recommends screening by asking questions about unhealthy drug use in adults age 18 years or older. Screening should be implemented when services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred."

Reference: Unhealthy drug use: Screening. Recommendation: Unhealthy Drug Use: Screening | United States Preventive Services Taskforce. (2020, June 9). Retrieved from https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/drug-use-illicit-screening

The Healthcare Effectiveness Data and Information Set (HEDIS®) is a registered trademark of NCQA. The NCQA HEDIS measure specification has been adjusted pursuant to NCQA's *Rules for Allowable Adjustments of HEDIS*. The adjusted measure specification may be used only for internal quality improvement purposes. Updated 2/1/2022



All summaries of the measures contained herein are reproduced with permission from HEDIS[®] Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA).

The information presented herein is for informational and illustrative purposes only. It is not intended, nor is it to be used, to define a standard of care or otherwise substitute for informed medical evaluation, diagnosis and treatment which can be performed by a qualified medical professional. Molina Healthcare, Inc. does not warrant or represent that the information contained herein is accurate or free from defects.

COPYRIGHT NOTICE AND DISCLAIMER

The HEDIS[®] measures and specifications were developed by and are owned by NCQA. The HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures and specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Use of the *Rules for Allowable Adjustments of HEDIS* to make permitted adjustments of the materials does not constitute a modification. Any commercial use and/or internal or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA's Measure Certification Program.

Reprinted with permission by NCQA. ©2021 NCQA, all rights reserved.

Limited proprietary coding is contained in the measure specifications for convenience. NCQA disclaims all liability for use or accuracy of any third-party code values contained in the specifications.

The American Medical Association holds a copyright to the CPT® codes contained in the measure specifications.

The American Hospital Association holds a copyright to the Uniform Billing Codes ("UB") contained in the measure specifications. The UB Codes in the HEDIS specifications are included with the permission of the AHA. The UB Codes contained in the HEDIS specifications may be used by health plans and other health care delivery organizations for the purpose of calculating and reporting HEDIS measure results or using HEDIS measure results for their internal quality improvement purposes. All other uses of the UB Codes require a license from the AHA. Anyone desiring to use the UB Codes in a commercial product to generate HEDIS results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact ub04@aha.org.

